Xenon Pharmaceuticals Dirección
Dirección controles de criterios 2/4
El CEO de Xenon Pharmaceuticals es Ian Mortimer , nombrado en Mar 2018, tiene una permanencia de 6.67 años. compensación anual total es $10.12M, compuesta por 6.6% salario y 93.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.06% de las acciones de la empresa, por valor de $1.80M. La antigüedad media del equipo directivo y de la junta directiva es de 4.3 años y 3.7 años, respectivamente.
Información clave
Ian Mortimer
Chief Executive Officer (CEO)
US$10.1m
Compensación total
| Porcentaje del salario del CEO | 6.6% |
| Permanencia del CEO | 6.7yrs |
| Participación del CEO | 0.06% |
| Permanencia media de la dirección | 4.3yrs |
| Promedio de permanencia en la Junta Directiva | 3.7yrs |
Actualizaciones recientes de la dirección
We Think The Compensation For Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) CEO Looks About Right
May 29
Recent updates
We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Oct 20Xenon Pharmaceuticals: Good Data In Epilepsy, But Doubts Remain
Aug 09Is There An Opportunity With Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) 37% Undervaluation?
Aug 09Xenon Pharmaceuticals (NASDAQ:XENE) Is In A Good Position To Deliver On Growth Plans
Jul 05We Think The Compensation For Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) CEO Looks About Right
May 29Calculating The Fair Value Of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Apr 16Here's Why We're Not Too Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Situation
Mar 12Xenon Pharmaceuticals: Analysts Still Positive Despite Recent Trial 'Setbacks'
Feb 08Here's Why We're Not Too Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Situation
Oct 21We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Jun 22We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely
Feb 15We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Oct 27Xenon started at outperform at Raymond James on experimental epilepsy drug
Oct 19Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Could Be 31% Below Their Intrinsic Value Estimate
Sep 22Putting Xenon Pharmaceuticals Back In The Spotlight
Sep 06Xenon initiated with Buy at BofA citing potential of anti-seizure drug
Aug 29Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) Intrinsic Value Is Potentially 67% Above Its Share Price
Jun 13Sizing Up Xenon Pharmaceuticals
Dec 13We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely
Nov 12We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Aug 05Industry Analysts Just Upgraded Their Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Revenue Forecasts By 6.4%
May 13We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely
Apr 14Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$213m |
| Jun 30 2024 | n/a | n/a | -US$199m |
| Mar 31 2024 | n/a | n/a | -US$189m |
| Dec 31 2023 | US$10m | US$666k | -US$182m |
| Sep 30 2023 | n/a | n/a | -US$176m |
| Jun 30 2023 | n/a | n/a | -US$165m |
| Mar 31 2023 | n/a | n/a | -US$148m |
| Dec 31 2022 | US$9m | US$595k | -US$126m |
| Sep 30 2022 | n/a | n/a | -US$113m |
| Jun 30 2022 | n/a | n/a | -US$91m |
| Mar 31 2022 | n/a | n/a | -US$83m |
| Dec 31 2021 | US$4m | US$524k | -US$81m |
| Sep 30 2021 | n/a | n/a | -US$66m |
| Jun 30 2021 | n/a | n/a | -US$59m |
| Mar 31 2021 | n/a | n/a | -US$37m |
| Dec 31 2020 | US$2m | US$462k | -US$29m |
| Sep 30 2020 | n/a | n/a | -US$28m |
| Jun 30 2020 | n/a | n/a | -US$28m |
| Mar 31 2020 | n/a | n/a | -US$38m |
| Dec 31 2019 | US$2m | US$421k | -US$42m |
| Sep 30 2019 | n/a | n/a | -US$39m |
| Jun 30 2019 | n/a | n/a | -US$44m |
| Mar 31 2019 | n/a | n/a | -US$42m |
| Dec 31 2018 | US$923k | US$342k | -US$34m |
| Sep 30 2018 | n/a | n/a | -US$34m |
| Jun 30 2018 | n/a | n/a | -US$27m |
| Mar 31 2018 | n/a | n/a | -US$27m |
| Dec 31 2017 | US$945k | US$312k | -US$31m |
Compensación vs. Mercado: La compensación total de Ian($USD10.12M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD6.60M).
Compensación vs. Ingresos: La compensación de Ian ha aumentado mientras la empresa no es rentable.
CEO
Ian Mortimer (48 yo)
6.7yrs
Permanencia
US$10,117,829
Compensación
Mr. Ian C. Mortimer, M.B.A, C.P.A, C.M.A., has been the Chief Executive Officer and Director at Xenon Pharmaceuticals Inc. since June 03, 2021. He has been an Independent Director at Perimeter Medical Imag...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 6.7yrs | US$10.12m | 0.060% $ 1.8m | |
| Chief Financial Officer | 3.4yrs | US$3.52m | 0% $ 0 | |
| Executive Vice President of Strategy & Innovation | no data | US$2.37m | sin datos | |
| Chief Commercial Officer | 4.3yrs | US$2.76m | 0.0053% $ 158.4k | |
| Chief Medical Officer | 3.3yrs | US$3.58m | 0% $ 0 | |
| Chief Legal Officer & Corporate Secretary | 2yrs | US$3.55m | sin datos | |
| Executive Vice President of Human Resources | 5.2yrs | sin datos | sin datos | |
| Executive Vice President of Drug Discovery | 8.8yrs | US$545.00k | sin datos | |
| Executive Vice President of R&D Operations | 4.3yrs | sin datos | sin datos |
4.3yrs
Permanencia media
54.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de XENE se considera experimentado (4.3 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 3.4yrs | US$10.12m | 0.060% $ 1.8m | |
| Independent Director | 1.3yrs | US$770.91k | sin datos | |
| Independent Director | 20.8yrs | US$560.09k | 0.038% $ 1.1m | |
| Independent Director | 4yrs | US$559.58k | sin datos | |
| Independent Director | 9.5yrs | US$561.42k | 0.0026% $ 79.2k | |
| Independent Chairman | 8.2yrs | US$588.37k | 0.033% $ 989.2k | |
| Independent Director | 1.3yrs | US$770.91k | sin datos | |
| Independent Director | 3.4yrs | US$548.57k | sin datos |
3.7yrs
Permanencia media
61.5yo
Promedio de edad
Junta con experiencia: La junta directiva de XENE se considera experimentada (3.7 años de antigüedad promedio).